Tanya Tang, DO
Nephrology · Spartanburg, SCNPI 1528388030
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,026 of the $11,070 with a category attached, or 81.5%. It is spread thinly across 36 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.
Across 439 payments — averaging $25.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$2K
- Amgen$878
- Otsuka America Pharmaceutical, Inc.$833
- ANI Pharmaceuticals, Inc.$766
- AstraZeneca$751
- Travere Therapeutics, Inc.$715
- plus $5K from 30 others
What the payments were for
- Consulting fees$1,63815%
- Food & beverage$9,02682%
- Education$4074%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 35 | $2,143 |
| Amgen(2 entities) | 41 | $878 |
| Otsuka America Pharmaceutical, Inc. | 77 | $833 |
| ANI Pharmaceuticals, Inc. | 25 | $766 |
| AstraZeneca(2 entities) | 41 | $751 |
| Travere Therapeutics, Inc. | 16 | $715 |
| Calliditas Therapeutics US Inc. | 23 | $647 |
| Bayer | 28 | $627 |
| Mallinckrodt Hospital Products Inc. | 18 | $497 |
| Novartis | 18 | $433 |
| Akebia Therapeutics Inc | 17 | $413 |
| GSK | 19 | $387 |
| Mallinckrodt Enterprises LLC | 15 | $315 |
| Novo Nordisk | 10 | $249 |
| Inari Medical, Inc. | 4 | $235 |
| Ardelyx, Inc. | 8 | $182 |
| Aurinia Pharma U.S., Inc. | 7 | $138 |
| Recor Medical Inc | 1 | $125 |
| Fresenius USA Marketing, Inc. | 7 | $124 |
| Boehringer Ingelheim | 4 | $103 |
| Stryker | 1 | $73 |
| Lilly USA, LLC | 4 | $69 |
| Daiichi Sankyo Inc. | 4 | $63 |
| Kyowa Kirin, Inc. | 2 | $53 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $35 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Baxter Healthcare | 2 | $24 |
| Lundbeck LLC | 1 | $21 |
| Rockwell Medical, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Cormedix Inc. | 1 | $18 |
| OPKO Pharmaceuticals, LLC | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,070 in reported general payments places this provider in the 85th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 23 | $31,039 |
| AuryxiaFerric Citrate | 15 | $28,683 |
| JardianceEmpagliflozin | 13 | $12,133 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $10,309 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $8,413 |
| Chlorthalidone | 290 | $4,881 |
| Calcium Acetate | 58 | $4,677 |
| Bumetanide | 45 | $2,701 |
| Spironolactone | 194 | $1,686 |
| Amlodipine Besylate | 212 | $1,280 |
| Losartan Potassium | 121 | $1,277 |
| Hydralazine Hcl | 56 | $1,232 |
| Carvedilol | 133 | $1,119 |
| Midodrine Hcl | 23 | $937 |
| Nifedipine ErNifedipine | 42 | $928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $124 | $31,03923 claims |
| Akebia Therapeutics IncAuryxia | $413 | $28,68315 claims |
| Boehringer IngelheimJardiance | $103 | $12,13313 claims |
| AstraZenecaLokelma | $751 | $8,41312 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $766 | $32513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Spartanburg
- Subhashini SubramaniamSpartanburg$13K
- Muhammad EbrahimSpartanburg$13K
- Lawrence McGeeSpartanburg$11K
- Matthew LambertSpartanburg$9K
- Kofi AppiahSpartanburg$7K
- Charles MurdockSpartanburg$7K
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.